Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

20.17
-0.2500-1.22%
Volume:815.38K
Turnover:16.65M
Market Cap:1.95B
PE:-3.46
High:20.68
Open:20.52
Low:20.12
Close:20.42
52wk High:42.37
52wk Low:18.41
Shares:96.48M
Float Shares:92.79M
Volume Ratio:0.54
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8316
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-22.03%
PB:-24.32
PE(LYR):-3.46

Loading ...

Ultragenyx Investors File Securities Class Action Lawsuit

Reuters
·
Feb 26

Ultragenyx to Participate at Investor Conferences in March

GlobeNewswire
·
Feb 24

Ultragenyx Faces Securities Class Action as Lead Plaintiff Deadline Nears

Reuters
·
Feb 23

FDA accepts Ultragenyx DTX401 BLA for priority review in GSDIa with Aug. 23, 2026 PDUFA date

Reuters
·
Feb 23

Ultragenyx Pharmaceutical Inc - FDA Grants Priority Review With Pdufa Date August 23, 2026

THOMSON REUTERS
·
Feb 23

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (Bla) for Dtx401 Aav Gene Therapy for Glycogen Storage Disease Type Ia (Gsdia)

THOMSON REUTERS
·
Feb 23

Ultragenyx Pharmaceutical Inc - IF Approved, Dtx401 to Be Manufactured in U.S. at Bedford Facility

THOMSON REUTERS
·
Feb 23

Rosen Law Firm Urges Ultragenyx Investors to Act Before April 6 Lead Plaintiff Deadline

Reuters
·
Feb 21

Ultragenyx Grants 22,917 RSUs to Six Newly Hired Officers Under Inducement Plan

Reuters
·
Feb 21

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 21

Schall Law Firm Files Securities Fraud Class Action Against Ultragenyx Pharmaceutical Inc

Reuters
·
Feb 21

Levi & Korsinsky Files Securities Class Action Against Ultragenyx Pharmaceutical Inc

Reuters
·
Feb 20

Ultragenyx Faces Securities Class Action as Lead Plaintiff Deadline Nears

Reuters
·
Feb 19

Ultragenyx FY 2025 Evkeeza product sales jump to USD 59 million (+84%)

Reuters
·
Feb 19

Ultragenyx Lawsuits Add Legal Overhang To Setrusumab Setback And 2027 Goals

Simply Wall St.
·
Feb 19

Ultragenyx Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Feb 18

Ultragenyx Faces Securities Class Action After Stock Plunge

Reuters
·
Feb 18

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Feb 17

Ultragenyx price target lowered to $37 from $39 at Evercore ISI

TIPRANKS
·
Feb 17

Ultragenyx Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 17